- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03901781
Study of ST266 Given by Intranasal Delivery in Glaucoma Suspect Subjects
A Dose-escalating Phase 1 Open-label Safety Study of ST266 Given by Non-invasive Intranasal Trans-cribriform Delivery in Glaucoma Suspect Subjects Without Evidence of Glaucomatous Damage.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed Informed Consent Form and HIPAA (Health Insurance Portability and Accountability Act) document.
- Male or Female, Ages 20-75 years.
- Must be clinically followed as a glaucoma suspect without evidence of glaucomatous damage.
- Must have one of the following: 1) IOP ≤ 28 mmHg and at least one (1) IOP measurement > 21 mmHg, or 2) physiologic cupping of the optic nerve, or 3) a family history of glaucoma.
- Two (2) normal visual fields (VF) both Swedish Interactive Threshold Algorithm - Short-wavelength Automated Perimetry (SITA-SWAP) and 24-2 VF prior to subject enrollment at the Baseline Visit.
- Two (2) normal Ocular Coherence Tomography (OCT) (of macula and nerve fiber layer) prior to subject enrollment at the Baseline Visit.
- Gonioscopy open to at least scleral spur with normal iris configuration.
- Normal baseline neuro-cognitive testing.
- Normal baseline Magnetic Resonance Imaging (MRI), including expected age-related changes, performed with and without contrast.
- Cohort Three group only: Baseline Lumbar Puncture within normal limits.
Exclusion Criteria:
Females of Child Bearing Potential (FOCBP) who are pregnant or lactating or who will not abstain from sexual activity for 14 days prior to Visit 1, and willing to remain so through 30 days following completion of the subject's first menstrual cycle following the End of Treatment (EOT) Visit. Alternatively, a WOCBP who will not remain abstinent must have been using one of the following acceptable methods of birth control for the times specified:
- IUD in place for at least three (3) months prior to Visit 1 until completion of the subject's first menstrual cycle following the EOT Visit.
- Barrier method (condom or diaphragm) with spermicide for at least three (3) months prior to Visit 1 through completion of the subject's first menstrual cycle following the EOT Visit.
- Stable hormonal contraceptive for at least three (3) months prior to Visit 1 through completion of the subject's first menstrual cycle following the EOT Visit. NOTE: For Depo-Provera injection contraceptives, the statement regarding first menstrual cycle following administration of the study product is not applicable as females receiving this form of contraception will not have menses.
- In a monogamous relationship with a surgically sterilized (i.e., vasectomized) partner at least six (6) months prior to Visit 1.
- Have undergone one of the following sterilization procedures at least six (6) months prior to Visit 1: Bilateral tubal ligation, Hysterectomy, Hysterectomy with unilateral or bilateral oophorectomy, Bilateral oophorectomy.
- Unwillingness to submit a urine pregnancy test at screening if of childbearing potential.
Male subjects who refuse to use one of the following birth control methods:
- Abstinence from the time of consent and through the duration of their participation in the protocol
- Barrier method (condom or diaphragm) with spermicide from time of consent through the duration of their participation in the protocol
- Surgical sterilization (vasectomy) at least 6 months prior to consent.
- IOP greater than 29 mmHg in either eye.
- Patients with high risk factors of ocular hypertension, such as thin central corneas, as identified by the Principal Investigator who may benefit from earlier treatment will be excluded.
- Evidence of Angle closure.
- Recent laser or incisional glaucoma surgery.
- Subjects who are currently taking glaucoma medications. Subject who can safely stop taking these medications during washout period (4-6 weeks) may be considered.
- Intranasal polyp or any head and/or neck neoplasm.
- History of or evidence on physical examination including endoscopy of sinus or nasal pathology, nasal passage obstruction, chronic sinus infections, or severe seasonal allergies.
- Currently using medications given intranasally.
- Subject is taking any anticoagulant medication such as heparin, low molecular weight heparin, Coumadin, or antiplatelet agents including low dose aspirin.
- History of stroke or Trans-Ischemic Attack (TIA) within the past five (5) years.
- Neuro-cognitively impaired as assessed by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).
- Subjects who have participated in an investigational product trial within the past 30 days.
- Subjects who refuse any part of the protocol assessments.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort One
Three (3) subjects, ST266 200 µL administered by trans-cribriform intranasal device once a day for 14 days using alternating sides (nostrils) with a follow-up visit at seven (7) days following End of Treatment (EOT), a follow-up call at one (1) month, and follow-up visits at three (3) months, six (6) months and 12 months following EOT.
|
ST266 administered by non-invasive trans-cribriform intranasal delivery using the SipNose intranasal device.
|
Experimental: Cohort Two
Three (3) subjects, ST266 400 µL administered by trans-cribriform intranasal device bilaterally (200 µL/nostril) once a day for 14 days with a follow-up visit at seven (7) days following EOT, a follow-up call at one (1) month, and follow-up visits at three (3) months, six (6) months and 12 months following EOT.
|
ST266 administered by non-invasive trans-cribriform intranasal delivery using the SipNose intranasal device.
|
Experimental: Cohort Three
Three (3) subjects, 400 µL ST266 administered by trans-cribriform intranasal device bilaterally (200 µL/nostril) once a day for 28 days with a follow-up visit at seven (7) days following EOT, a follow-up call at one (1) month, and follow-up visits at three (3) months, six (6) months and 12 months following EOT.
|
ST266 administered by non-invasive trans-cribriform intranasal delivery using the SipNose intranasal device.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Time Frame: 18 months (entire duration of study)
|
Safety will be determined by comparing the results of the screening tests at baseline and again at the end of the treatment period through the end of study.
Adverse events (AEs) and Serious Adverse Events (SAEs) will be recorded.
The primary safety variable is the incidence of subjects with any adverse event during the entire study.
|
18 months (entire duration of study)
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ST266-IOPHTN-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ocular Hypertension
-
Western Galilee Hospital-NahariyaUnknown
-
Laboratoires TheaCompletedOcular Hypertension GlaucomaBulgaria
-
Santen Inc.Completed
-
West Virginia UniversityUniversity of PittsburghRecruitingGlaucoma and Ocular HypertensionUnited States, United Kingdom, Canada
-
University Hospital, GenevaTerminatedGlaucoma and Ocular HypertensionSwitzerland
-
Santen Inc.Completed
-
Maastricht University Medical CenterCompletedCorticosteroid Induced Ocular Hypertension/GlaucomaNetherlands
-
Santen Inc.CompletedA Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHTGlaucoma and Ocular HypertensionUnited States
-
Bausch & Lomb IncorporatedCompletedGlaucoma | Open Angle or Ocular HypertensionUnited States
-
Nicox Ophthalmics, Inc.CompletedGlaucoma, Open-Angle | Hypertension, OcularUnited States
Clinical Trials on ST266 via Intranasal Delivery
-
Bastyr UniversityNational Center for Complementary and Integrative Health (NCCIH)Completed
-
The Cleveland ClinicUniversity of Washington; University of California, San FranciscoRecruitingMultiple SclerosisUnited States
-
Akouos, Inc.Eli Lilly and CompanyRecruitingSensorineural Hearing Loss, BilateralUnited States, Taiwan
-
Institute of Cancer Research, United KingdomCancer Research UK; University of Manchester; University of SussexCompletedBreast Neoplasm FemaleUnited Kingdom
-
Windtree TherapeuticsCompletedRespiratory Distress SyndromeUnited States, Canada, Colombia, Hungary, Chile, Ireland, Netherlands, Poland
-
Dr. David MasloveIronstone Professional DevelopmentCompleted
-
Laval UniversityUnknown
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingRecurrent Glioblastoma | Recurrent Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II GliomaUnited States
-
Cerebral Therapeutics LLCTerminated